HaDEA has published a call for tenders HADEA/2023/OP/0036 – “Speed up the development of and access to innovative medical countermeasures” with an estimated budget of €82 million.
The subject of this call for tenders is to conclude service contracts for the purchasing of clinical and non-clinical services to speed up availability and access to innovative medical countermeasures (MCMs). The innovative MCMs include promising solutions that are indicated to diagnose/detect, prevent, protect from or treat conditions associated to serious cross border health threats.
Lot 1 Vaccines to Combat Antimicrobial Resistance (AMR) aims to speed up the development of vaccine candidates targeting bacterial infections as an alternative treatment strategy to address the rising incidence of AMR.The identified vaccine candidates shall be designed to target bacteria belonging to at least one of the twelve bacterial families classified as ‘priority pathogens’ in the 2017 WHO Bacterial Priority Pathogens List.
Estimated budget: €22 million
Lot 2 Broad Spectrum Antivirals against Respiratory Diseases will support the development of broad-spectrum antivirals targeting respiratory RNA viral families, such as Paramyxo-, Orthomyxo and Coronaviridae.
Estimated budget: €18 million
Lot 3 Broad Spectrum Antivirals Targeting Viral Families Known for Causing Viral Haemorrhagic Fever (VHF) will support the development of broad-spectrum antivirals targeting viral families known for causing viral haemorrhagic fever (VHF), such as Arena-, Bunya-, Flavi-, Filoviridae.
Estimated budget: €18 million
Lot 4 Point of Care Metagenomic Sequencing for Universal Pathogen Detection supports the development of a metagenomic next-generation sequencing (mNGS)-based test that can detect any respiratory viral pathogen, including novel and emerging, from human respiratory samples.
Estimated budget: €24 million
All interested parties are invited to send in their applications by 4 December 2023, 16:00 (CEST).
See the call documents and apply on the eTendering portal.
